CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
BeOne Medicines
Children's Hospital of Philadelphia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Genmab
AbbVie
Genmab
FBD Biologics Limited
Janssen Research & Development, LLC
AbbVie
Calibr, a division of Scripps Research
Hoosier Cancer Research Network
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Georgetown University
Actuate Therapeutics Inc.
Medical College of Wisconsin
American Society of Clinical Oncology
Pfizer
Acerta Pharma BV
Colorado State University
AIDS Malignancy Consortium
Washington University School of Medicine
AbbVie
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Janssen Biotech, Inc.
University of Oslo
St. Jude Children's Research Hospital
Zagazig University
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Children's Oncology Group
University of Ulm
Mayo Clinic
M.D. Anderson Cancer Center
Cancer Research UK
Arkansas Children's Hospital Research Institute
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Children's Hospital Medical Center, Cincinnati
University of Heidelberg Medical Center
Essen Biotech